¹⁷⁷Lu-DOTA-EB-FAPi is a new therapeutic agent from the FAPi family. Fibroblast Activation Protein (FAP) is highly expressed in cancer associated fibroblasts (CAFs) which are found in the majority of cancer types. To limit the rapid clearance of FAPi, ¹⁷⁷Lu-DOTA-EB-FAPi incorporates Evans Blue (EB) structure to bind albumin which improves its pharmacokinetics and pharmacodynamics.

Besides cancer, FAPis may also be used for benign diseases such as fibroses, Atherosclerosis, rheumatoid arthritis, sarcoidosis, etc. In this specific molecule, the first human trials focuses on thyroid cancer. Of course, this molecule has potential largely beyond thyroid cancer.

Target/Mechanism: Fibroblasts

Carrier/Ligand: FAPI

Radiation Type: beta electrons (β^–)